Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 55Lung Neoplasms 32Breast Neoplasms 29Small Cell Lung Carcinoma 23Neoplasms 21Triple Negative Breast Neoplasms 18Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Melanoma 14Colorectal Neoplasms 14Glioblastoma 10Prostatic Neoplasms 9Ovarian Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Liver Neoplasms 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Mesothelioma, Malignant 7Uterine Cervical Neoplasms 6Sarcoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Kidney Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Squamous Cell 5Pancreatic Neoplasms 4

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Safety Issues × atezolizumab × Clear all
NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Unknown
25 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡